Clinical Trials Browser

Phase 2/3 × INDUSTRY × surufatinib × Clear all

NCT06361888 2025-12-30

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Phase 2/3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03873532 2020-02-13

A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

Phase 2/3 Unknown

Gastrointestinal

Biliary Tract Neoplasms